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Summary
Aims. We investigated the potential activity of STI571 on signal transduction pathways
and its pro-apoptotic effect in osteosarcoma cell lines expressing PDGF and its receptor.
Materials and Methods. SCF-receptor and PDGF-receptor expression was evaluated in
five human osteosarcoma cell lines by cytofluorimetry and immunohistochemistry. The
activation status of these receptors was analysed by immunoprecipitation studies in basal
conditions, after stimulation with PDGF, and after stimulation with PDGF and inhibition
with STI571, simultaneously. We detected the presence of PDGF in culture media using
an Enzyme-Linked ImmunoSorbent Assay. We then performed apoptosis analysis by Ter-
minal desoxy-Uridine Nucleotide Extending Labelling (TUNEL) assay with a scalar con-
centration of STI571 at 24 and 48 hours.
Results. Four cell lines were positive for PDGF-Rβ, one for PDGF-Rα and one slightly
positive for both receptors. We observed low levels of c-Kit expression. Detectable levels
of PDGF were found in all the supernatants analysed. Immunoprecipitation studies
showed a receptor constitutive phosphorilation in basal conditions, amplification of this
status with exogenous PDGF and a dose-dependent inhibition by STI571.
Discussion. STI571 might interfere with osteosarcoma proliferative signals in vitro by se-
lective inhibition of PDGF-R, suggesting a potential use of this drug in association with
traditional antineoplastic agents.
Riassunto
Obiettivi. Abbiamo valutato i potenziali effetti pro-apoptotici di STI571 su linee cellu-
lari di osteosarcoma umano esprimenti il PDGF ed il suo recettore.
Materiali e metodi. Attraverso indagine citofluorimetrica ed immunocitochimica abbi-
amo analizzato l’espressione dei recettori per il PDGF e lo SCF su 5 linee cellulari di
osteosarcoma. Lo stato di attivazione di tali recettori è stato valutato attraverso studi
di immunoprecipitazione in condizioni basali, dopo stimolazione con PDGF e dopo con-
temporanea stimolazione con PDGF ed inibizione con STI571. Attraverso test immu-
noenzimatici abbiamo ricercato la presenza del PDGF nel surnatante delle linee cellu-
lari. Infine, abbiamo valutato l’apoptosi indotta da concentrazioni scalari di STI571 dopo
24 e 48 ore.
Risultati. Quattro linee cellulari esprimevano il PDGF-Rβ, una esprimeva il PDGF-Rα
ed un’altra esprimeva debolmente entrambi i recettori; abbiamo osservato bassi livelli
di espressione del c-kit. Inoltre, nei surnatanti delle linee cellulari era presente il PDGF.
Gli studi di immunoprecipitazione hanno infine evidenziato una costitutiva fosforilazione
del PDGF-R in condizioni basali, un’amplificazione di tale stato dopo stimolo esogeno
con PDGF ed una inibizione dose-dipendente dopo aggiunta di STI571.
Discussione. STI571 può interferire in vitro con il segnale proliferativo dell’osteosar-
coma attraverso inibizione selettiva del PDGF-R, suggerendone un possibile impiego in
associazione alla chemioterapia tradizionale.
Introduction
Osteosarcoma is the most common primary malignant bone tumour in chil-
dren. Its prognosis remains poor despite recent advances, with a 5-year sur-
vival rate of 40-50% for patients with metastatic disease at diagnosis 1. For 
patients with osteosarcoma in metastatic relapse 2 over-
all survival rates are between 20 and 25% after metas-
tasectomy and aggressive second line chemotherapy.
These results in poor prognosis patients underline the
need for additional therapies to preserve complete re-
mission. Several studies 3 4 show that an aberrant acti-
vation of tyrosine kinase receptors such as Stem Cell
Factor receptor (c-kit) or Platelet Derived Growth Fac-
tor-Receptor (PDGF-R) protect tumour cells against
apoptosis and enhance their invasive potential, sug-
gesting an autocrine and paracrine mechanism between
receptors and their ligands.
Platelet Derived Growth Factor (PDGF) is a major mi-
togen for fibroblasts, smooth muscle cells and other
cells of mesenchymal origin; it plays a central role in
regulating cell proliferation, chemotaxis and survival in
normal cells as well as in various disease states such as
cancer, arteriosclerosis and fibrotic disease. The
PDGF/PDGF-R system involves two receptors (PDGF-
R α and PDGF-R β) and four ligands (PDGF-A, B, C
and D). The binding of PDGF determines receptor
dimerisation, structural changes and autophosphoryla-
tion and subsequent activation of an intracytoplasmic
cascade that leads to multiple events such as cytoskele-
tal changes, gene transcription, cell motility, cell pro-
liferation, cell differentiation, cell scattering and many
others 5.
Coexpression of PDGF and its receptor has been ob-
served in various human tumours including menin-
gioma, astrocytic glioma and other brain tumours,
melanoma, ovarian cancer, neuroendocrine tumours,
pancreatic cancer, gastric cancer and prostate cancer 6 7.
Similar data about a Stem Cell Factor (SCF)-dependent
autocrine loop in neuroblastoma cell lines and primary
tumours were reported by our group 8 9. Autocrine or
paracrine stimulation of c-kit was also described in Ew-
ing sarcoma – the second most common bone tumour in
children and adolescents 10 – and in uveal melanoma 11.
Coexpression of c-kit and its ligand SCF mRNA in syn-
ovial sarcoma was described by Tamborini et al. 12, who
also recently investigated the simultaneous expression
of c-kit and PDGF-R β in this tumour, suggesting a mu-
tually exclusive expression of the two receptors 13. Se-
lective inhibition of these growth factor-receptor sig-
nalling loops may represent a new treatment strategy
for managing osteosarcoma as well as other types of
cancer. Co-targeting more protein tyrosine kinases
might also represent a new therapeutic approach, to ob-
tain a synergetic effect in proliferation inhibition and
apoptosis induction 14.
At present, tyrosine kinase inhibitors include multiple
agents, some of these in early clinical development:
Trastuzumab, which inhibits Her2/neu in breast cancer;
Cetuximab, which inhibits Epidermal Growth Factor
Receptor (EGFR) in colorectal cancer; ZD1839, which
targets EGFR in non-small cell lung cancer; OSI-774,
which inhibits EGFR in pancreatic cancer and many
others 15.
STI571 or Imatinib, a 2-phenylaminopyrimidine deriv-
ative, is a well-known inhibitor of the proto-oncogene
c-abl, the bcr-abl fusion protein – derived from the
chromosomal translocation t(9;22) – and PDGF-R ty-
rosine kinases 16. New approaches using this drug in
GastroIntestinal Stromal Tumors (GISTs) are showing
encouraging results 17: moreover on February 1st 2001,
Imatinib mesylate was approved by the United States
Food and Drug Administration for the treatment of ma-
lignant metastatic and/or unresectable GISTs 18.
There is also a potential role for STI571 in other tu-
mours bearing c-kit abnormalities, such as small cell
lung cancer 19.
The therapeutic efficacy of STI571 on osteosarcoma is
now the object of increasing attention. Recent studies
have shown an over-expression of PDGF and its recep-
tors 20 and the presence of c-kit on the surface of human
osteosarcoma cells 21, thus predicting an efficacy of
STI571 also in osteosarcoma. Therefore, our study fo-
cused on the anticancer activity of STI571 in human
osteosarcoma cells in vitro.
In this study, we analysed the expression of PDGF and
its receptors in osteosarcoma cell lines and investigat-
ed a potential interference of STI571 on its signal trans-
duction pathways (modulation of the receptor activa-
tion status) and its possible pro-apoptotic effect.
Materials and methods
CELL LINES
We analysed five human osteosarcoma cell lines: MG-
63, HOS, SJSA-1, U-2 OS, Saos-2, obtained from the
American Type Culture Collection. MG-63 and HOS
cell lines were maintained in Eagle’s Minimum Essen-
tial Medium (EMEM, EuroClone), while SJSA-1, U-2
OS and Saos-2 cell lines were maintained in Roswell
Park Memorial Institute Medium (RPMI, Sigma), both
supplemented with 10% Foetal Bovine Serum (FBS)
and 0.5 mg/ml penicillin/streptomycin. The human
chronic myelogenous leukaemia cell line K562, ex-
pressing c-kit, was used as a control.
CYTOFLUORIMETRIC DETECTION OF SURFACE
C-KIT AND PDGF-R α AND β CHAINS
Five x 105 cells were incubated with anti-CD117 phy-
coerythrin (PE)-conjugated monoclonal antibody
(MoAb) (Caltag) and anti α and β chain of PDGF-R
MoAb (R&D System), at 4 °C for 30 minutes, then
washed twice in Phosphate-Buffered Saline (PBS). An-
other incubation with Fluoresceine Isotyocianate
(FITC)-conjugate Goat anti-Mouse secondary antibody
and two further washes were performed to identify
PDGF-R. All samples were analysed by flow cytome-
try (FACS Calibur, Becton Dickinson). PE and FITC
conjugated isotypic antibodies were used as controls.
To quantify the average number of receptors per cell,
the Quantum (TM) 27 R-Phycoerythrin-conjugated kit
(Dako) was used. This contains a set of calibrated stan-
dards, with four populations of microbeads displaying
increasing and predetermined fluorescence intensity
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(expressed in terms of number of Molecules of Equiv-
alent Soluble Fluorochromes [MESF]) and one blank
reference population. Using this method, the relative
channel number obtained by flow cytometry analysis of
a cell population was directly transformed into the
number of MESF.
IMMUNOHISTOCHEMISTRY FOR C-KIT AND PDGF-
R α AND β EXPRESSION
To detect the presence of PDGF-R α and β chains on
the osteosarcoma cell surface we used the commercial
EnVision + System-Peroxidase kit (DAKO), according
to the manufacturer’s protocol.
IMMUNOPRECIPITATION STUDIES
The c-kit and/or PDGF-R positive cell lines were
analysed for the phosphorylation of these receptors in
different conditions: 1) basal condition; 2) stimulation
with exogenous PDGF 10 ng/ml for 10 minutes; 3)
stimulation with PDGF for 10 minutes plus inhibition
with scalar doses of STI571 (1, 10 and 50 µM) for 90
minutes. Cells were then resuspended in serum-free
medium and incubated for 24 hours at 37 °C 5% CO2.
STI571 treated and untreated cells were rapidly pellet-
ed and resuspended in lysis buffer (10 mmol/l trisHCl,
pH 8.6; 1.5 mmol/l MgCl2; 0.14 mol/l NaCl; 1%
NP40; 2 mmol/l phenylmethylsulfonylfluoride; 2
µg/ml leupeptin; 2 µg/ml aprotinin; 1 mg/ml pepsin).
The lysates were incubated for a minimum of 30 min-
utes on ice, frozen, thawed, and centrifuged at 13,000
rpm at 4 °C for 20 minutes. Immunoprecipitation of c-
kit and PDGF-R α and β chains were performed on the
clarified supernatant with specific MoAb (R&D Sys-
tems) coupled to sepharose-protein (Sigma Chemical,
St Louis, MO). After incubation for 16 hours at 4 °C,
immunoprecipitates were washed, first with lysis
buffer without NP-40, then with tris HCl 50 mmol/l,
pH 6.5. After elution of samples from proteins with
Sodium Dodecyl Sulphate (SDS) a sample buffer was
carried out. The resulting proteins underwent a 7%
SDS-PolyAcrylamide Gel Electrophoresis (PAGE).
The proteins were electrophoretically transferred to ni-
tro-cellulose filters, which had been incubated
overnight at 4 °C with a 3% albumin bovine (Sigma)
blocking solution in TBS-Tween buffer (20 mmol/L
Tris HCl, pH 7.6; 137 mmol/L NaCl; 0.1% Tween 20).
Antiserum anti-phosphotyrosine PY20 (Transduction
Laboratories, Lexington, KY) was added to the solu-
tion and incubated for 2 hours at room temperature.
The filters were then washed three times for 10 min-
utes with PBS-Tween buffer and incubated for 1 hour
at room temperature with a horseradish peroxidase-
conjugated (Biorad) rabbit anti-mouse antibody. The
filters were washed as above and visualised using Im-
mun-Star Chemiluminescent Protein Detection System
(Biorad). The mean of intensity of the bands visualised
on the x-ray film was semiquantitatively evaluated
with Quantity One Software (Biorad) and expressed as
intensity (INT).
DETECTION OF SOLUBLE SCF AND PDGF
PRODUCTION BY TUMOUR CELL LINES
To detect and quantify the presence of PDGF soluble
forms -AA, -BB and -AB, we harvested the media of
all cell lines in basal serum-free conditions and after 24
and 48 hours of incubation with STI571 at concentra-
tions of 0.1, 1 and 10 µM. We used an ELISA method
(Quantikine, R&D Systems) with a sensitivity of 4
pg/mL.
EVALUATION OF APOPTOSIS BY TUNEL ASSAY
ANALYSIS
The cells were cultured in serum-free conditions with
and without STI571 at a scalar concentration (0.1, 1, 10
µM) for 24 and 48 hours. The cells were fixed by
adding formaldehyde (1% in PBS) for 15 minutes on
ice. After resuspension in PBS, the cells were stored at
4 °C in ethanol (70% in PBS). To perform the apopto-
sis analysis, the cells were rehydrated in PBS and then
washed twice with PBS and incubated with a cacody-
late buffer containing 5 U of Terminaldesossinu-
cleotidylTransferase (TdT) (Boehringer) and 0.5
µmol/L of FITC-desoxyUridineTriPhosphate (Caltag)
for 1 hour at 37 °C. The cells were rinsed in PBS and
incubated with 0.4 µg/mL propidium iodide for 30 min-
utes before cytofluorimetric analysis.
Results
CYTOFLUORIMETRIC DETECTION OF SURFACE
C-KIT AND PDGF-R α AND β CHAINS
Surface expression of PDGF receptor α and β chains
and c-kit was tested in basal culture conditions in all
five cell lines. Four cell lines (HOS, SJSA-1, Saos-2
and U-2 OS) were positive for PDGF-R β, though with
a different expression as shown in Table I. The control
K562 cell line also showed a low positivity for PDGF-
R β and only the MG-63 cell line had a high positivity
for PDGF-R α expression. The Saos-2 cell line was
weakly positive for both PDGF-R β and c-kit. All the
osteosarcoma cell lines analysed showed low levels of
MESF values of c-kit expression, with the MESF value
comparable with the blank control, except for a weak
expression in Saos-2. Therefore, in our subsequent ex-
periments we focused our attention on the study of
PDGF and its receptors (Fig. 1).
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Tab. I. MESF value of the cells positive for PDGF-R α and β and for
c-kit in all the osteosarcoma cell lines analysed.
PDGF-R α PDGF-R β c-KIT
HOS 0,00 72720,18 0,00
MG-63 116220,50 0,00 0,00
SAOS-2 0,00 784,90 120,80
SJSA-1 0,00 76872,80 0,00
U-2 OS 0,00 22625,57 0,00
K562 0,00 4561,37 114571,84
IMMUNOHISTOCHEMISTRY FOR C-KIT AND PDGF-
R α AND β EXPRESSION
Immunohistochemistry analysis confirmed these re-
sults. PDGF-R expression was revealed by small
brown granulation on the cell surface, for membrane
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Fig. 1. Cytofluorimetric detection of PDGF-R β, in HOS cell line (A,
B), Saos-2 cell line (C, D), SJSA-1 cell line (E, F), U-2 OS cell line (G,
H); PDGF-R α expression in MG-63 cell line (I, L). Cytofluorimetric
analysis of the cells stained with isotypic antibody (negative con-
trol) (left); histograms of the positive cells (right).
Fig. 2. Immunohistochemistry for PDGF-R α and β expression: in
MG-63 cell line (A: negative control, B: PDGF-R α expression),
SAOS-2 cell line (C: negative control, D: PDGF-R β expression),
SJSA-1 cell line (E: negative control, F: PDGF-R β expression) (m.o.
100x), HOS cell line (G negative control, H PDGF-R β expression;
m.o. 20x), U-2 OS cell line (I negative control, L PDGF-R β expres-
sion; m.o. 100x). PDGF-R expression is evident as a small brown
granulation.
receptor, or in the cytoplasm, for internalised forms
(Fig. 2).
IMMUNOPRECIPITATION STUDIES
We tested the ability of PDGF to induce receptor tyro-
sine phosphorilation and the capacity of STI571 at con-
centrations of 1, 10 and 50 µM to inhibit the PDGF re-
ceptor kinase activity in the cell lines MG-63, HOS,
SJSA-1 and U-2 OS. As shown in Figure 3, all the cell
lines analysed showed a receptor constitutive phospho-
rilation in basal conditions (experimental condition 6)
and this activation status increased after addition of ex-
ogenous PDGF according to exposure time (experi-
mental conditions 1, 2). Inhibition of activation status
of PDGF-R was dose-dependent, with the highest inhi-
bition observed with 50 µM (experimental conditions
3, 4, 5). The activation status of PDGF-R was not down
modulated after incubation with STI571 10 µM only.
The modulation of the PDGF-R α and β chains on the
cell lines analysed was similar in all the experimental
conditions proposed. We found that PDGF activates its
receptors and this activation is effectively inhibited by
STI571 from 1 to 50 µM.
DETECTION OF PDGF PRODUCTION BY TUMOUR
CELL LINES
We studied the concentration of PDGF-AA, PDGF-AB
and PDGF-BB in the culture media of HOS, U-2 OS,
SJSA-1 and MG-63 cell lines without STI571, and in
presence of rising concentrations (1, 10, 50 µM) of in-
hibitor after 24 and 48 hours.
We observed high levels of PDGF-AA isoform in the
HOS cell line (range 974.5-1353.7 pg/ml at 24 hours
and 1653.9-2043.1 pg/ml at 48 hours), in the U-2 OS
cell line (range 2529.8-2861.4 pg/ml at 24 hours and
2727.5-3169.2 pg/ml at 48 hours) and in the SJSA-1
cell line (range 811.8-1278.6 pg/ml at 24 hours and
939.5-1638.9 pg/ml at 48 hours). No evidence of
PDGF-AA was found in the MG-63 cell line. The
PDGF-AB isoform was detectable in lower concentra-
tions in the HOS cell line (range 345-687.5 pg/ml at 24
hours and 532.7-1616.1 pg/ml at 48 hours); for U-2
OS, PDGF levels were between 932.3 and 1630.4
pg/ml at 24 hours and between 1555.8 and 2037.7
pg/ml at 48 hours. PDGF-BB concentration was not
significant in any of the cell lines analysed. The results
are shown in Figure 4.
EVALUATION OF APOPTOSIS
The effect of STI571 treatment on apoptosis was tested
24 and 48 hours after STI571 addition by the TUNEL
assay method, using K562 as a drug-sensitive cell line.
Only a small fraction of the cell lines analysed under-
went apoptosis: two out of five cell lines showed apop-
tosis ranging from 23.45% in HOS to 24.07% in SJSA-
1, as shown in Figure 5. After 48 hours, only one cell
line (Saos-2) showed apoptosis (28.05%). These levels
of apoptosis were observed at a STI571 concentration
of 10 µM.
Discussion
The prognosis of patients with high grade osteosarco-
ma has greatly improved over the past 25 years, with
overall survival rates rising from 15% to 70%. This im-
provement is attributed to: a) the effect of preoperative
chemotherapy; b) the introduction of aggressive
chemotherapy with different combinations of high dose
methotrexate, doxorubicin, cisplatinum and ifos-
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Fig. 3. Immunoprecipitation studies: modulation of the activation status of PDGF-R α chain in MG-63 (A) and of PDGF-R β chain in HOS (B),
SJSA-1 (C) and U-2OS (D). Left: the illustration of Western Blotting analysis; right: the semi-quantitive analysis histograms of the mean in-
tensity (INT) of the bands visualised on the x-ray film and analysed by Quantity One software (Biorad). In all cell lines the different experi-
mental conditions (Lines 1-7), indicated in the legend on the right-hand, showed an activation status of the PDGF-R in basal condition (Line
6) that increases after adding exogenous PDGF according to exposure time (Lines 1 and 2) and decreases after stimulation with STI571 in
a dose dependent manner (Lines 3, 4, 5). The condition without stimulation with exogenous PDGF, and only with STI571 10 µM (Line 7) did
not show a decrease of the activation status compared to the basal condition.
 
famide; c) the identification of a dose-response rela-
tionship with methotrexate, doxorubicin, cisplatinum;
d) the recognition of the histological response to pre-
operative chemotherapy as the main prognostic factor
that might change the postoperative chemotherapy 22-24.
The prognosis of patients with osteosarcoma in
metastatic relapse is very poor, with overall survival
rates between 20%-25% after metastasectomy and ag-
gressive second line chemotherapy 2. These results in
poor prognosis patients underline the need for addi-
tional therapies to maintain complete remission and to
eliminate the minimal residual disease. The aim of our
study was to evaluate the potential anticancer activity
of STI571 in human osteosarcoma cells in vitro. Our
results showed that all the cell lines analysed express,
in different percentages, PDGF-R, while only a very
low expression of c-kit was assessable on the Saos-2
cell line. Therefore, we primarily focused our attention
on the role of PDGF and its receptor in anti-apoptotic
pathways and on a potential effect of STI571 in this
signalling. A constitutive phosphorilation of PDGF-R
Western Blotting was revealed by western blotting
analysis in basal conditions. Furthermore, ELISA stud-
ies suggest that this constitutive activation status might
be sustained by the endogenous production of the
PDGF ligand by osteosarcoma cells. This data demon-
strated an autocrine/paracrine mechanism dependant on
PDGF/PDGF-R pathway involved in the pathogenesis
of osteosarcoma. The production of PDGF after stimu-
lation with STI571 showed differing modulations in the
cells lines, in terms of drug doses and stimulation times
at 24 and 48 hours in the osteosarcoma cell lines
analysed. For example, in the U-2 OS cell line, the
PDGF-AB concentration after 24 and 48 hours of phar-
macological treatment increases with higher drug con-
centrations (Fig. 4B: a-b); the same trend is slightly ev-
ident for PDGF-AA isoform after 48 hours (Fig. 4A: b).
However, PDGF-AB production by the HOS cell line
after 48 hours of Imatinib treatment showed a decreas-
ing trend, probably due to the different biological and
proliferative responses of cell lines to the drug. (Fig.
4B: b). Nevertheless, immunoprecipitation studies
showed a slight dose-dependent inhibition of PDGF-R
after the addition of increasing concentrations of
STI571, suggesting a short-term interference of this
drug in intracellular signalling processes. We then tried
to verify whether this signal interference by STI571 de-
termines programmed cell death or apoptosis. Using
the TUNEL assay method, we measured the number of
apoptotic cells 24 and 48 hours from the addition of
scalar concentrations of STI571. We observed the high-
est levels of apoptosis in SJSA-1, HOS (24.07% and
23.45% after 24 hours respectively) and in the Saos-2
cell line (28.05% after 48 hours). Preliminary data
seem to suggest that the inhibition of the proliferative
message arising from tyrosine-kinase receptors such as
PDGF-R might be considered as a molecular target ap-
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Fig. 4A. Concentration of PDGF-AA isoform in the supernatants
of HOS, U-2 OS, SJSA-1 without (basal condition: ctrl) and with
STI571 1, 10, 50 µM at 24 (a) and 48 hours (b).
Fig. 4B. Concentration of PDGF-AB isoform in the supernatants
of HOS, U-2 OS, SJSA-1 without (basal condition: ctrl) and with
STI571 1, 10, 50 µM at 24 (a) and 48 hours (b).
Fig. 5. Apoptosis study by TUNEL assay: in the histogram the
apoptotic cells are identified as cells positive to the BrdU FITC an-
tibody. The experimental conditions are given in the legend and
were tested on the SJSA-1 (A) and HOS (B) cell line after 24 hours;
on the Saos-2 cell line after 24 (C) and 48 (D) hours; on U-2 OS cell
line after 24 (E) and 48 (F) hours. We used K562 as a drug-sensi-
tive line (G).
a b
a b
proach in osteosarcoma therapy. Nevertheless, apopto-
sis data suggest a possible involvement of numerous
signalling pathways insensitive to STI571 inhibition. A
more complete approach might be the association of
different tyrosine-kinase inhibitors that would interfere
at multiple levels with the neoplastic signal.
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